AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

EQRx Launches to Create Innovative Medicines at Dramatically Lower Prices for People, Healthcare Systems and Society

January 12, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 12, 2020--

EQRx announced today that it is launching to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems. EQRx, a first of its kind biotechnology company, is focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. Leveraging advances in science and technology to bring treatments for life threatening and chronic diseases to people more efficiently and cost-effectively, EQRx intends to offer its therapies at dramatically lower prices compared to today’s innovative medicines.

“Over the last several decades, society has benefited from unprecedented technological advances and a deeper understanding of disease biology, revolutionizing the way many diseases are treated today. That said, the pricing of new therapeutic approaches is pushing beyond the limits of common sense, preventing people and society from equally benefiting from innovation,” said Alexis Borisy, chairman and chief executive officer of EQRx. “The time is now for a market-based solution to rising drug costs. Our blue-chip team of founders and leaders is proud to launch EQRx and to lead the way in redefining what it means to innovate and deliver high-quality medicines that are within reach of people through more equitable prices.”

“The process of developing and bringing new drugs to market should and can be organized towards the goal of their being affordable both for patients and society,” said Peter Bach, MD, co-founder of EQRx and director of the Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center. “Today even people with insurance are delaying filling prescriptions or going without due to the high cost sharing that is ‘part and parcel’ of high drug prices. New approaches are needed. EQRx aims to create affordable new medicines that are priced for access, and accessibility is the critical attribute for every medicine if it is going to improve people’s health.”

Series A Funding

EQRx is launching with $200 million in Series A financing led by GV, ARCH Venture Partners, Andreessen Horowitz, and Casdin Capital, Section 32, Nextech and Arboretum Ventures, among others.

“The bold mission of EQRx to deliver better medicines at lower prices is one that can redefine the therapeutics landscape,” said Krishna Yeshwant, MD, general partner, GV. “The company’s business model will deliver a sustainable approach for creating, reinvesting in, and rewarding therapeutics innovation, while ensuring these new medicines are broadly accessible to people and healthcare systems through dramatically lower pricing.”

Expert Team of Founders and Leaders

EQRx has assembled a team of life sciences enterprise leaders including:

About EQRx

EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. Headquartered in Cambridge, Massachusetts, the company is backed by GV, ARCH Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32, Nextech, and Arboretum Ventures. For additional information, please visit www.eqrx.com.

Follow us on twitter: @EQRxINC

View source version on businesswire.com:https://www.businesswire.com/news/home/20200112005044/en/

CONTACT: For media, please contact:

Dan Budwick

1AB

dan@1abmedia.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH OTHER HEALTH HEALTH PHARMACEUTICAL

SOURCE: EQRx

Copyright Business Wire 2020.

PUB: 01/12/2020 10:30 AM/DISC: 01/12/2020 10:30 AM

http://www.businesswire.com/news/home/20200112005044/en